ARS Pharmaceuticals, Inc. Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
ARS Pharmaceuticals, Inc. (SPRY) had Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount of $46.90 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions · last filed 2026-08-13
- 2026-06-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $46.90M.
- 2026-03-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $65.00M.
- 2025-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $42.40M.
- 2025-09-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $48.30M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount |
|---|---|
| 2026-06-30 | $46.90M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $65.00M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $42.40M 10-K · filed 2026-03-09 |
| 2025-09-30 | $48.30M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $53.90M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $54.50M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $41.10M 10-K · filed 2025-03-20 |
| 2024-09-30 | $37.00M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $31.60M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $32.80M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $22.70M 10-K · filed 2024-03-21 |
| 2023-09-30 | $27.60M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $30.20M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $29.10M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $4.60M 10-K · filed 2023-03-23 |
| 2022-09-30 | $30.70M 10-Q · filed 2022-11-02 |
| 2022-06-30 | $44.20M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $49.70M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $50.50M 10-K · filed 2022-03-31 |
| 2021-09-30 | $56.70M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $60.40M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $59.60M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |